Although targeting the Ras/Raf/MEK pathway remains a promising anticancer strategy, MEK inhibitors in clinical development are likely to be limited in their ability to produce durable clinical responses due to the emergence of acquired drug resistance. To identify potential mechanisms of such resistance, we established MEK inhibitor-resistant clones of human HT-29 colon cancer cells (HT-29R cells) which harbor the B-Raf V600E mutation. HT-29R cells were specifically resistant to MEK inhibition in vitro and in vivo, with drug-induced elevation of MEK/ERK and their downstream targets primarily accountable for drug resistance. We identified MEK1(F129L) mutation as a molecular mechanism responsible for MEK/ERK pathway activation. In an isogenic cell system that extended these findings into other cancer cell lines, the MEK1(F129L) mutant exhibited higher intrinsic kinase activity than wild type (WT) MEK1, leading to potent activation of ERK and downstream targets. The MEK1(F129L) mutation also strengthened binding to c-Raf, suggesting an underlying mechanism of higher intrinsic kinase activity. Notably, the combined use of Raf and MEK inhibitors overcame the observed drug resistance and exhibited greater synergy in HT-29R cells as compared to the drug-sensitive HT-29 parental cells. Overall, our findings suggested that mutations in MEK1 can lead to acquired resistance in patients treated with MEK inhibitors, and that a combined inhibition of Raf and MEK may be potentially useful as a strategy to bypass or prevent drug resistance in the clinic.
Introduction
Current cancer drug development is evolving towards treatment with molecularly targeted agents, driven by the discovery of genetic alterations in cancer and the signaling pathways they alter. In some patients with cancers driven by a "driver" oncogene, targeted therapies have shown remarkable improvements in clinical response and survival.
Successful examples include imatinib in chronic myelogenous leukemia (CML) with
BCR-ABL translocation (1, 2) and in gastrointestinal stromal tumors (GIST) with activating c-KIT or platelet-derived growth factor receptor mutation (3), gefitinib and erlotinib in non-small cell lung cancers harboring an activating epidermal growth factor receptor (EGFR) mutation (4) , and trastuzumab in breast cancer with Her-2 amplification (5). On the other hand, the rapid acquisition of drug resistance often limits the overall therapeutic impact. This highlights the need for greater understanding of intrinsic (de novo) or acquired resistance mechanisms of the targeted therapy.
Oncogenic Ras and B-Raf mutations frequently occur in human tumors. Ras mutations are found in ~ 30% of human tumors (6) . B-Raf mutations also occur in many cancers, with the highest incidence in melanoma (60-70%) (7) . Ras or B-Raf mutations lead to aberrant activation of the Ras/Raf/MEK/ERK signal cascade which correlates with tumor progression and poor prognosis (8) . The Ras/Raf/MEK pathway components have therefore become attractive targets for cancer therapy. Many new agents have entered human clinical trials targeting Raf or MEK. RG7204/PLX4032 (Vemurafenib), an orally selective B-Raf inhibitor, exhibits impressive antitumor activity in B-RafV600E mutant metastatic melanomas (9, 10) and significantly improved patient survival (2011 ASCO).
A companion diagnostic test to select B-RafV600E mutant tumors is necessary (11, 12, 13, 14) . Highly selective MEK inhibitors (GSK1120212, AZD6244, GDC-0973/XL518, RO4987655) evaluated in early clinical studies may provide benefit in a broader patient population carrying B-Raf wild type or Ras mutant tumors. To date, the observed clinical response for MEK inhibitors as single agents has been encouraging but limited (15. 16, 17) . This is likely resulted from potent MEK inhibition in normal cells leading to a narrow therapeutic window. Limited durable efficacy of MEK inhibitors may also result from de novo or drug acquired resistance in cancers due to complicated signaling pathway cross-talk and compensatory feedback regulation. Thus, it is important to have a better understanding of the molecular mechanism underlying acquired resistance. In this study, we established the colorectal cancer cell (HT-29R) clones resistant to MEK inhibition by chronically exposing HT-29 cells to RO4927350, a highly selective MEK inhibitor (18) . HT-29 parental cells harbor B-RafV600E mutation and are highly sensitive to MEK inhibition. We compared molecular profiles of sensitive cells (HT-29S) and resistant cells (HT-29R) to reveal potential molecular mechanisms underlying MEK inhibitor acquired resistance leading to a rational therapeutic strategy to overcome such resistance. 
Materials and Methods

Compounds
RO4927350 was synthesized according to the procedure described in patent application (WO2006018188). Raf inhibitor PLX4032 was synthesized in house. MEK inhibitor RO4987655/CH4987655 was synthesized by Chugai Pharmaceuticals, Japan. MEK inhibitor PD0325901, Raf inhibitor PLX4720, Sorafenib, paclitaxel, doxorubicin, and irinotecan were purchased from American Chemicals Custom Corporation, ChemieTek or Sigma Aldrich.
Cell lines and antibodies
The HT-29 cell line was purchased from ATCC and maintained in the designated medium. Antibodies against RAS, p-ERK1/2 (Thr202/Tyr204), p-MEK1/2 (Ser217/221), MEK1/2, p-RSK (Ser380), RSK, p-MNK (Thr197/202), MNK, p-BAD (Ser112), pp85/70 S6 kinase (Thr421/Ser424), p-S6 ribosomal protein (Ser235/236), p-S6 ribosomal protein (Ser240/244), p-CREB (Ser133), DUSP-6, p-AKT (Ser473), p-4E-BP (Thr37/46), p-4E-BP (Ser65), p-4E-BP (Thr70), p-mTOR (S2481) and p-mTOR (S2448) were purchased from Cell Signaling Technology. Anti-B-RAF, anti-c-RAF, anti-β-actin were purchased from Santa Cruz Biotechnology, BD Transduction Laboratories, and Sigma Aldrich, respectively. Anti-Dusp-10 is from Abnova (Walnut, CA, USA). Anti-ERK is from Millipore.
Generation of the MEK inhibitor resistant clones (HT-29R)
HT-29 cells were cultured in the presence of gradually increasing concentrations of RO4927350 up to 20 µM. After 10 months, HT-29R resistant clones were selected and 6 maintained in the presence of 5 µM of RO4927350. HT-29S control clones were selected by the same single cell subclonal procedure in the absence of the drug. for exons 5 and 6.
Sequencing of B-Raf
Western blot analysis and cell viability assays in vitro
Western blot and MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assays were carried out as previously described (18) . The CellTiter-Glo luminescent cell viability assays (Promega) were carried out according to the manufacturer's instruction.
For combination MTT assays, cells were simultaneously treated with various concentrations of two agents at a fixed ratio across a range of activities. Cell viability was evaluated after 5 days using the MTT assay. The isobologram and combination index (CI) were calculated according to the Chou and Talalay median effect principal using Calcusyn software version 2 (Biosoft). The computed isobologram is a graphical representation of the two agent interaction and is formed by plotting the individual drug doses required to achieve a single agent effect on their respective x and y axes; a line connecting the two points is drawn. Combination data points that fall on, above or below the line respectively represent additive, antagonism or synergy. The calculated CI values provide a qualitative measure of the degree of drug interaction in terms of additive effect (CI = 1), synergism (CI < 1), or antagonism (CI > 1) for a given endpoint of the effect measurement such as EC 50 or EC 90 .
Plasmid constructs and transfection
Human full length wild type (WT) MEK1 and mutant MEK1(F129L) expression vectors were cloned into vector pCMV6 with myc-DDK tag at its C-terminus (from Origene).
The mutation of MEK1(F129L) was generated by mutagenesis changing C387 to A and mutation was confirmed by sequencing. HEK293 cells were transfected with MEK1(WT)
or MEK1(F129L) expression vector using lipofectamine 2000 (Invitrogen).
Immunoprecipitation-Western blot analysis.
Cells were transfected with flag-tagged MEK1 (WT or F129L) plasmids with or without B-RafV600E cotransfection. After 48 hours, cells were lysed and immunoprecipitation (IP) was performed using anti-FLAG M2 affinity gel (Sigma). Immune complexes were analyzed by Western blotting. For in vitro kinase assays, the bound protein was eluted with FLAG peptides and the FLAG-tagged proteins (MEK1 WT or F129L) were analyzed by Western blotting and quantified by measuring band density against various concentrations of FLAG standard loaded on the same gel.
In vitro kinase assays and compound IC 50 determination by IMAP assay MEK kinase activity was determined by IMAP assay as previously described (18) 
In vivo efficacy studies in xenograft tumor models
In vivo testing was done as previously described (19) The HT-29 colorectal cancer cell line was previously shown to harbor the B-RafV600E mutation and is highly sensitive to MEK inhibition (18, 19) . To explore potential mechanisms of drug acquired resistance, we exposed HT-29 cells to gradually increasing On the other hand, HT-29R and HT-29S clones showed equivalent sensitivity (less than 2 fold difference in both IC 50 and IC 90 ) to Sorafenib, a non-selective Raf inhibitor, and other agents with different mechanism of action (paclitaxel, doxorubicin and irinotecan) ( Table 1 ). These results demonstrate that HT-29R clones are specifically resistant to MEK/Raf inhibition suggesting the acquired resistance mechanism is likely involved in pathway specific dysregulation.
Acquired resistance to MEK inhibition is associated with an elevation of the
Raf/MEK/ERK pathway activity
To understand how the Raf/MEK/ERK pathway is dysregulated in HT-29R cells, we 
An activating mutation MEK1(F129L) was identified in HT-29R cells
To understand the underlying mechanism for pathway elevation in HT-29R cells, we profiled HT-29R versus HT-29S to identify potential genetic alterations. We performed 
MEK1(F129L) exhibits higher intrinsic kinase activity, binds c-Raf stronger compared to wild type MEK1 and confers resistance to MEK inhibition
To validate MEK1(F129L) as an activating mutation, we directly measured kinase activity of the purified MEK1(F129L) proteins in a cell-free system. The FLAG-tagged MEK1(WT) and MEK1(F129L) proteins were purified from HEK293 transfectants by using an anti-FLAG M2 affinity gel. Total levels of purified FLAG-MEK1 (WT and F129L) were comparable, but pMEK levels were significantly higher in the F129L preparation (upper panel in Figure 4C ). MEK1 enzyme (WT and F129L) activities were measured in vitro in a cell-free system by quantitating the phosphorylation of ERK peptide using the IMAP assay. Furthermore, we examined the dose-response effect of the MEK inhibitor (RO4987655) on MEK1 (WT or F129L) with or without the addition of cRaf (lower panel in Figure 4C ). In the absence of c-Raf, MEK1(WT) showed negligible basal enzyme activity, whereas MEK1(F129L) displayed higher basal enzyme activity than MEK1(WT) correlating with observed higher pMEK levels within MEK1(F129L) Figure 4D ). These results suggest that the increased intrinsic kinase activity of MEK1(F129L) may be due to its stronger binding affinity to c-Raf which leads to a sustained MEK activation.
To confirm these findings in cancer cell lines natively harboring the B-RafV600E mutation, MEK1(WT) and MEK1(F129L) were expressed in A375 melanoma cells.
Comparable levels of WT and F129L MEK1 were expressed (detected by anti-FLAG, anti-MEK1 and anti-pMEK1/2 antibodies, lower panels, Figure 5A ). The MEK1(F129L) specifically induced ERK phosphorylation (upper panel, Figure 5A ), bound more c-Raf but not B-Raf ( Figure 5B ) and displayed significant resistance to MEK inhibition, as evidenced by a 10-fold-increase in the IC 50 ( Figure 5C 
Discussion
Acquired drug resistance remains the major challenge to targeted cancer therapy which leads to patient relapse with limited survival benefit (25) . Therefore, it is important to identify mechanisms underlying acquired resistance. By continuously exposing cancer cells to a highly selective anti-cancer agent in vitro over a period of time, the majority of cells are eliminated and only drug resistant clones are expanded. This is a experimental strategy that has been successfully used to identify MET amplification as a mechanism of acquired resistance to EGFR kinase inhibitor in non-small cell lung cancer (NSCLC) (26) , and c-Raf overexpression as a potential mechanism of acquired resistance to B-Raf inhibitor in melanoma (27) . In this study, we established a cell model system (HT-29R) resistant to MEK and Raf inhibitors by using the same approach. HT-29R was derived from the chronic exposure of HT-29 colorectal cells to a highly selective MEK inhibitor, RO4927350. HT-29 cells harboring the B-RafV600E mutation are originally sensitive to MEK inhibition (18, 19) . By comparative profiling of sensitive and resistant clones, we Figure 2) . mTOR is autophosphorylated at Ser2481 and phosphorylated at Ser2448 via both PI3K/AKT and or p70 S6 kinase signaling pathways (33, 34) . Interestingly, pmTOR(S2448) is significantly higher in HT-29R (1 and 9) carrying the MEK1(F129L) mutation. We showed MEK1(F129L) induced p70 S6 kinase activity (Figure 4) . It has been reported that p70S6 kinase is a major effector of mTOR phosphorylation at Ser-2448 (34). These results suggest that MEK1(F129L) induces p70 S6 kinase activation leading to the elevation of p-TOR(S2448). Elevated mTOR phosphorylation in HT-29R 
observed in both sensitive and resistant clones, unlike combination of Raf and MEK inhibitors, comparable CI values were seen (data not shown.) consistent with the lack of elevation of p-AKT and p-4EBP1 levels in HT-29R cells compared to HT-29S cells (Suppl. Figure 2) .
Our data support the need to monitor MEK1 mutation in the clinic during MEK inhibitor treatment as these may indicate that drug acquired resistance is occurring in the tumor.
RO4987655 is in early clinical development (21). We examined MEK1 exon sequences in four archived pre-dose tumors from melanoma and colorectal patients, as expected there was no mutation found (data not shown). In the future, it will be interesting to 
